gnbt fact sheet generex
biotechnology corporation .
investor fact
sheet
at a
glance :
symbol nasdaqsc :
gnbt
price ( 3 / 4 / 05 ) :
$ 0 . 61
52 - week
high / low :
$ 0 . 58 / $ 1 . 86
av .
volume ( 3 - mo ) :
303 , 681
shares
outstanding : 34 . 76
million
float :
29 . 6
million
%
held
by insiders :
14 . 83 %
market
capitalization : $ 21 . 20
million
cash : * $ 1 . 76
million
long - tem
debt : * $ 935 , 000
revenue * *
$ 710 , 000
* as of 10 / 31 / 04
* * 12 months ended
10 / 31 / 04
insulin
without pain , ready for market
- - generex
biotechnology ( nasdaqsc : gnbt ) has developed
oral - lyn  , an oral insulin spray for the treatment of
diabetes ,
thereby replacing insulin injections .
- - after 10 years of
development , oral - lyn  has been found to be as effective as injected
insulin and
is ready for commercialization .
- - sales could start as early as
the
first half of 2005 in south
america . canada and europe is the next target market , with
u . s . and
europe to
follow .
- - diabetes is growing at
epidemic
rates . hundreds of millions suffer from type 1 , type 2 or pre - diabetes .
even
modest penetration of the worldwide diabetes market would translate into
revenues
in the billion - dollar range .
- - generex  s
delivery system , rapidmist  , has the potential to
replace
injected drugs , including morphine , fentanyl ,
heparin
and flu vaccine .
why buy now
generex
biotechnology is a toronto - based , delaware corporation with a market - ready
solution to a central challenge in diabetes treatment  ending the pain and
hassle of insulin injections . ever since scientists early in the 20 th
century
learned that diabetes was caused by the body  s inability to produce a
normal
supply of insulin , patients have had to administer insulin by injection .
alternatives
that have been developed in recent years  pumps or needle - less  pens  
are
still invasive and / or expensive . pharmaceutical companies have tried to
develop
a truly non - invasive insulin product that is pain - free , easy to use and
free from
serious side effects .
among
today  s competing technologies , only oral - lyn  ,
an
insulin spray to treatment diabetes , meets all those tests . after 10 years
of
development , oral - lyn  is ready for market and is
set
to produce enormous revenue growth for the company . generex
is little known outside a small community of investors focused on drug
delivery
and diabetes treatment . in the next few months , however , the expected
commercial
entry of oral - lyn  in south
america could raise generex  s
profile sharply , with a commensurate rise in their share price . small
companies
in drug and medical - device development are , of course , inherently high - risk
investments . but aggressive investors who take an early stake in these
firms
can profit several times over . generex has the
profile of being one such potential winner .
readers are advised that
this investor fact sheet is intended for informational use only . anyone interested in obtaining more
detailed
information about the company should contact generex
biotechnology ( generex ) or investor relations
international ( iri ) . this investment profile was developed as part of an
overall investor relations program with iri .
iri has been retained by generex to
provide
investor relations advisory services , for which iri receives compensation
in the
form of cash . this investment fact sheet is intended solely for
informational
purposes and is not to be construed as an offer to sell or the solicitation
of
an offer to buy the company ' s stock . this investment fact sheet is based
upon
information available to the public , as well as other information from
sources
deemed reliable , but is not guaranteed as being accurate nor does it
purport to
be complete . this investment fact sheet may contain forward - looking
statements
within the meaning of section 27 a of the securities act of 1933 , as
amended ,
and section 21 e of the securities exchange act of 1934 , as amended . these
forward - looking statements are subject to a variety of risks and
uncertainties ,
many of which are beyond generex  s control , which
could cause actual results to differ materially from those contemplated in
these forward - looking statements . existing and prospective investors are
cautioned not to place undue reliance on these forward - looking statements ,
which speak only as of the date hereof . for additional information
regarding
these and other risks faced by the company , visit the company  s website at
www . generex . com .
this message is sent to
you
in compliance with the federal can - spam bill and the electronic commerce
( ec
directive ) regulations of 2004 . this is a commercial email which includes
an
unsubscribe method for remove processing as mandated by law . footer also
includes
the sender ' s information . bizcap . info p . o . box 155 sugarloaf , ny . 10981 to be excluded from
future mailings , please reply to this email with rem
in the subject line .
gnbt fact sheet
generex
biotechnology corporation .
investor fact
sheet
at a
glance :
symbol nasdaqsc :
gnbt
price ( 3 / 4 / 05 ) :
$ 0 . 61
52 - week
high / low :
$ 0 . 58 / $ 1 . 86
av .
volume ( 3 - mo ) :
303 , 681
shares
outstanding : 34 . 76
million
float :
29 . 6
million
%
held
by insiders :
14 . 83 %
market
capitalization : $ 21 . 20
million
cash : * $ 1 . 76
million
long - tem
debt : * $ 935 , 000
revenue * *
$ 710 , 000
* as of 10 / 31 / 04
* * 12 months ended
10 / 31 / 04
insulin
without pain , ready for market
- - generex
biotechnology ( nasdaqsc : gnbt ) has developed
oral - lyn  , an oral insulin spray for the treatment of
diabetes ,
thereby replacing insulin injections .
- - after 10 years of
development , oral - lyn  has been found to be as effective as injected
insulin and
is ready for commercialization .
- - sales could start as early as
the
first half of 2005 in south
america . canada and europe is the next target market , with
u . s . and
europe to
follow .
- - diabetes is growing at
epidemic
rates . hundreds of millions suffer from type 1 , type 2 or pre - diabetes .
even
modest penetration of the worldwide diabetes market would translate into
revenues
in the billion - dollar range .
- - generex  s
delivery system , rapidmist  , has the potential to
replace
injected drugs , including morphine , fentanyl ,
heparin
and flu vaccine .
why buy now
generex
biotechnology is a toronto - based , delaware corporation with a market - ready
solution to a central challenge in diabetes treatment  ending the pain and
hassle of insulin injections . ever since scientists early in the 20 th
century
learned that diabetes was caused by the body  s inability to produce a
normal
supply of insulin , patients have had to administer insulin by injection .
alternatives
that have been developed in recent years  pumps or needle - less  pens  
are
still invasive and / or expensive . pharmaceutical companies have tried to
develop
a truly non - invasive insulin product that is pain - free , easy to use and
free from
serious side effects .
among
today  s competing technologies , only oral - lyn  ,
an
insulin spray to treatment diabetes , meets all those tests . after 10 years
of
development , oral - lyn  is ready for market and is
set
to produce enormous revenue growth for the company . generex
is little known outside a small community of investors focused on drug
delivery
and diabetes treatment . in the next few months , however , the expected
commercial
entry of oral - lyn  in south
america could raise generex  s
profile sharply , with a commensurate rise in their share price . small
companies
in drug and medical - device development are , of course , inherently high - risk
investments . but aggressive investors who take an early stake in these
firms
can profit several times over . generex has the
profile of being one such potential winner .
readers are advised that
this investor fact sheet is intended for informational use only . anyone interested in obtaining more
detailed
information about the company should contact generex
biotechnology ( generex ) or investor relations
international ( iri ) . this investment profile was developed as part of an
overall investor relations program with iri .
iri has been retained by generex to
provide
investor relations advisory services , for which iri receives compensation
in the
form of cash . this investment fact sheet is intended solely for
informational
purposes and is not to be construed as an offer to sell or the solicitation
of
an offer to buy the company ' s stock . this investment fact sheet is based
upon
information available to the public , as well as other information from
sources
deemed reliable , but is not guaranteed as being accurate nor does it
purport to
be complete . this investment fact sheet may contain forward - looking
statements
within the meaning of section 27 a of the securities act of 1933 , as
amended ,
and section 21 e of the securities exchange act of 1934 , as amended . these
forward - looking statements are subject to a variety of risks and
uncertainties ,
many of which are beyond generex  s control , which
could cause actual results to differ materially from those contemplated in
these forward - looking statements . existing and prospective investors are
cautioned not to place undue reliance on these forward - looking statements ,
which speak only as of the date hereof . for additional information
regarding
these and other risks faced by the company , visit the company  s website at
www . generex . com .
this message is sent to
you
in compliance with the federal can - spam bill and the electronic commerce
( ec
directive ) regulations of 2004 . this is a commercial email which includes
an
unsubscribe method for remove processing as mandated by law . footer also
includes
the sender ' s information . bizcap . info p . o . box 155 sugarloaf , ny . 10981 to be excluded from
future mailings , please reply to this email with rem
in the subject line .
